Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study (2008)

Peer-Reviewed Study · del Río-Garma J; Alvarez-Larrán A; Martínez C; Muncunill J; Castellà D; de la Rubia J; Zamora C; Corral M; Viejo A; Peña F; Rodríguez-Vicente P; Contreras E; Arbona C; Ramírez C; Garcia-Erce JA; Alegre A (and co-authors) · July 14, 2008

del Río-Garma J et al., 2008-07-14: Multicentre prospective cohort of 102 episodes of idiopathic TTP treated with plasma exchange: patients given methylene blue-photoinactivated plasma needed more exchanges and far more plasma to reach remission and relapsed more often than those given quarantine FFP.

In conclusion, MBPIP is less effective than qFFP in the treatment of TTP.

Abstract

del Río-Garma J et al., 2008-07-14: Multicentre prospective cohort of 102 episodes of idiopathic TTP treated with plasma exchange: patients given methylene blue-photoinactivated plasma needed more exchanges and far more plasma to reach remission and relapsed more often than those given quarantine FFP. Study type: multicentre prospective cohort (comparative), Spain. N=102 TTP episodes (63 MBPIP, 39 qFFP). Comparator: quarantine FFP. Primary endpoint: remission status on day 8. Result: OR 0.17 (0.06-0.47) for remission on day 8; more exchanges (median 11 vs 5) and more plasma (485 vs 216 mL/kg); more recrudescences (29/63 vs 8/39). Funding/COI not stated in retrieved abstract record. This is the strongest clinical 'cuts against' finding for MB plasma: the product is not clinically equivalent to untreated FFP in TTP. Study type: controlled study.